Related Experiment Videos
[Heart transplantation. Current status at La Pitié Hospital]
Insights
Heart transplantation offers improved survival rates for patients with severe myocardial damage. Advances in immunosuppression and diagnostics have significantly enhanced patient outcomes and long-term quality of life.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Context:
- Severe irreversible myocardial damage necessitates advanced treatment options.
- Heart transplantation has been performed since 1972 at La Pitié Hospital, Paris.
- Patient selection and transplant availability impact treatment accessibility.
Purpose:
- To evaluate the outcomes of heart transplantation in patients with severe myocardial damage.
- To assess the impact of evolving medical advancements on patient survival and quality of life.
- To analyze post-operative complications and long-term graft function.
Summary:
- Between 1972 and the study period, 66 heart transplantations were performed out of 280 referred patients.
- Common challenges included graft rejection and immunosuppression complications, with 47% achieving near-normal life post-transplant.
- Recent improvements in immunosuppressive agents (e.g., cyclosporin A) and diagnostics have boosted one-year survival to 77% and two-year survival to 70%.
Impact:
- Improved immunosuppressive strategies and diagnostic tools have significantly reduced early and late mortality.
- Heart transplants demonstrate durable functional properties, offering hope for prolonged and satisfactory survival.
- These advancements are crucial for enhancing long-term patient well-being and social reintegration post-transplantation.
Abstract:
Since 1972, 280 patients with severe irreversible myocardial damage have been referred to La Pitié Hospital, Paris, for heart transplantation; 95 were excluded on account of absolute contra-indications. Owing to the limited number of available transplants, only 66 of the 185 remaining patients were transplanted. Transplantation was orthotopic in all but 3 cases: 1 patient had heterotopic transplantation and 2 had heart-lung transplantation. The most common post-operative problems were graft rejection and complications of the immunosuppressive treatment; 82% of the transplanted patients were discharged 2 months on average after surgery; 47% overcame the first year problems and resumed an almost normal social and professional life; 21 are still alive, one of them after 9 years. During the last 2 years, technical refinements and the advent of more potent immunosuppressive agents (anti-lymphocyte serum from rabbits, cyclosporin A) and better diagnostic methods (repeated endomyocardial biopsies and immunological surveillance) have resulted in considerable improvement in the patients' outcome, with an actuarial survival rate of 77% at one year and 70% at two years. Since transplants are now better tolerated after the second year and since they possess remarkably good and durable functional properties, this reduction in early and late mortality, which used to be the main cause of failure, raises hopes of a marked increase in prolonged and satisfactory survival.